Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.76 |
| ▸ | MEN1 | O00255 | 4/20 | 0.76 |
| ▸ | PPIA | P62937 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.65 |
| ▸ | SCN1A | P35498 | 1/20 | 0.65 |
| ▸ | SCN4A | P35499 | 1/20 | 0.65 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.65 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.65 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.65 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.65 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.65 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1102252 | 0.86 | KMT2A (1.00) | KMT2AMEN1PPIASMN1; SMN2LMNA | |
| SCHEMBL1091178 | 0.86 | LMNA (0.74) | KMT2AMEN1PPIASMN1; SMN2LMNA | |
| SCHEMBL879585 | 0.84 | KMT2A (0.73) | KMT2AMEN1PPIASMN1; SMN2LMNA | |
| SCHEMBL1091420 | 0.84 | LMNA (0.79) | KMT2AMEN1PPIASMN1; SMN2LMNA | |
| SCHEMBL1091645 | 0.84 | TDP1 (0.73) | KMT2AMEN1PPIATDP1SCN3A | |
| SCHEMBL10031625 | 0.83 | KMT2A (0.71) | KMT2AMEN1PPIASMN1; SMN2LMNA | |
| SCHEMBL1101958 | 0.83 | MEN1 (0.75) | KMT2AMEN1PPIASMN1; SMN2LMNA | |
| SCHEMBL10031568 | 0.82 | KMT2A (0.77) | KMT2AMEN1PPIASMN1; SMN2LMNA | |
| SCHEMBL17689190 | 0.82 | MEN1 (0.79) | KMT2AMEN1SMN1; SMN2LMNATSHR | |
| SCHEMBL15116290 | 0.82 | KMT2A (0.74) | KMT2AMEN1PPIASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| US-8309543-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120238578-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-8202861-B2 | Drugs for various disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202861-B2 | Drugs for various disorders | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-19 | — | — | US | disclosed |
| US-8153655-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2332912-A1 | Heteroarylaminosulfonylphenylderivates for use as sodium or calcium channel blockers in the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-2327701-A1 | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-08 | — | — | US | disclosed |
| US-7615563-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-10 | — | — | US | disclosed |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-02-02 | — | — | US | disclosed |
| WO-2005013914-A2 | HETEROARYLAMINOSULFONYLPHENYL DERIVATIVES FOR USE AS SODIUM OR CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238578-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | SCNN1G, KCNN3, KCNN2 | KMT2A 3111/4885MEN1 2329/4885PPIA 2483/4885 |
| US-20100087479-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | KMT2A 3111/4885MEN1 2329/4885PPIA 2483/4885 |
| US-20060025415-A1 | Compositions useful as inhibitors of voltage-gated sodium channels | SCNN1G, KCNN3, KCNN2 | KMT2A 3111/4885MEN1 2329/4885PPIA 2483/4885 |
| US-20130184258-A1 | Compositions Useful as Inhibitors of Voltage-Gated Sodium Channels | SCNN1G, KCNN3, KCNN2 | KMT2A 3111/4885MEN1 2329/4885PPIA 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.